{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T04:16:32Z","timestamp":1781237792951,"version":"3.54.1"},"reference-count":101,"publisher":"Informa UK Limited","issue":"12","license":[{"start":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T00:00:00Z","timestamp":1660867200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007013","name":"F. Hoffmann-La Roche Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Leukemia &amp; Lymphoma"],"published-print":{"date-parts":[[2022,10,15]]},"DOI":"10.1080\/10428194.2022.2098291","type":"journal-article","created":{"date-parts":[[2022,8,19]],"date-time":"2022-08-19T08:23:42Z","timestamp":1660897422000},"page":"2765-2784","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":4,"title":["Utility of measurable residual disease for predicting treatment outcomes with BCR- and BCL2-Targeted therapies in patients with CLL"],"prefix":"10.1080","volume":"63","author":[{"given":"William G.","family":"Wierda","sequence":"first","affiliation":[{"name":"University of Texas MD Anderson Cancer Center","place":["Houston, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas J.","family":"Kipps","sequence":"additional","affiliation":[{"name":"UCSD Moores Cancer Center","place":["San Diego, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Othman","family":"Al-Sawaf","sequence":"additional","affiliation":[{"name":"Department I of Internal Medicine and Center of Integrated Oncology Cologne Aachen Cologne Bonn D\u00fcsseldorf, German CLL Study Group, University Hospital, University of Cologne","place":["Cologne, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brenda","family":"Chyla","sequence":"additional","affiliation":[{"name":"AbbVie Inc.","place":["North Chicago, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana M. L.","family":"Biondo","sequence":"additional","affiliation":[{"name":"Genentech, Inc.","place":["South San Francisco, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Mun","sequence":"additional","affiliation":[{"name":"Genentech, Inc.","place":["South San Francisco, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanwen","family":"Jiang","sequence":"additional","affiliation":[{"name":"Genentech, Inc.","place":["South San Francisco, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Seymour","sequence":"additional","affiliation":[{"name":"Peter MacCallum Cancer Centre, Royal Melbourne Hospital & University of Melbourne","place":["Melbourne, Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2022,8,19]]},"reference":[{"key":"e_1_3_5_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1908213"},{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0132-y"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00689"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2019.03.014"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.2688"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.36.9348"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-538116"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.1305"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-792333"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)61381-5"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30051-1"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1313984"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0554-1"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.4556"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-018-0037-8"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.09.019"},{"key":"e_1_3_5_18_1","unstructured":"FDA. Calquence. Highlights of prescribing information; 2021 [cited 2021 Jun 17]. Available from: https:\/\/www.azpicentral.com\/calquence\/calquence.pdf#page=1."},{"key":"e_1_3_5_19_1","unstructured":"FDA. Copiktra. Highlights of prescribing information; [cited 2021 Jun 17]. Available from: https:\/\/copiktra.com\/pdf\/verastem\/COPIKTRA-PI-072019.pdf."},{"key":"e_1_3_5_20_1","unstructured":"FDA. Imbruvica. Highlights of prescribing information; 2021 [cited 2021 Jun 17]. Available from: https:\/\/imbruvica.com\/files\/prescribing-information.pdf."},{"key":"e_1_3_5_21_1","unstructured":"FDA. Zydelig. Highlights of prescribing information; 2021 [cited 2021 Jun 17]. Available from: https:\/\/www.gilead.com\/\u223c\/media\/Files\/pdfs\/medicines\/oncology\/zydelig\/zydelig_pi.pdf."},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-06-093906"},{"key":"e_1_3_5_23_1","article-title":"Ibrutinib plus venetoclax in relapsed\/refractory CLL: results of the bloodwise TAP clarity study","volume":"185","author":"Munir T","year":"2019","unstructured":"Munir T, Rawstron A, Brock K, et\u00a0al. Ibrutinib plus venetoclax in relapsed\/refractory CLL: results of the bloodwise TAP clarity study. Br J Haematol. 2019;185, 25 (conference paper).","journal-title":"Br J Haematol"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-08-870238"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1509388"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1812836"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817073"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-127506"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-020-01010-6"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01460"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30788-5"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1080\/14737140.2020.1829482"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1713976"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1815281"},{"key":"e_1_3_5_35_1","doi-asserted-by":"crossref","unstructured":"Al-Sawaf O Zhang C Robrecht S et\u00a0al. Venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: 4-year follow-up analysis of the randomized CLL14 study. Abstract Book for the 26th Congress of the European Hematology Association Virtual Edition 2021 in HemaSphere: June 2021 - Volume 5; 2021 Jun 9\u201317.","DOI":"10.1002\/hon.49_2880"},{"key":"e_1_3_5_36_1","doi-asserted-by":"crossref","unstructured":"Kater AP Kipps T Eichhorst B et\u00a0al. Five-year analysis of Murano study demonstrates enduring undetectable minimal residual disease (uMRD) in a subset of relapsed\/refractory chronic lymphocytic leukemia (R\/R CLL) patients (pts) following fixed-duration venetoclax-rituximab (VenR) therapy (tx). American Society of Hematology Annual Meeting & Exposition (virtual) Blood (2020) 136 (Supplement 1): 19\u201321.","DOI":"10.1182\/blood-2020-136109"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01580"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018019422"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-01-761973"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020009578"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30012-8"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12874-018-0611-x"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-12-820910"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020010146"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0276-9"},{"key":"e_1_3_5_46_1","unstructured":"Al-Sawaf O Zhang C Tandon M et\u00a0al. Fixed-duration venetoclax-obinutuzumab for previously untreated chronic lymphocytic leukemia: follow-up of efficacy and safety results from the multicenter open-label randomized phase 3 CLL14 trial. Abstract Book for the 25th Congress of the European Hematology Association Virtual Edition 2020 in HemaSphere: June 2020 - Volume 4; 2020 Jun 11\u201321."},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30443-5"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8027"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.49_2880"},{"key":"e_1_3_5_50_1","doi-asserted-by":"crossref","unstructured":"Kater AP Arslan O Demikran F et\u00a0al. Efficacy of venetoclax in patients with relapsed\/refractory chronic lymphocytic leukemia: primary endpoint analysis of the international phase 3b trial (VENICE I). Abstract Book for the 25th Congress of the European Hematology Association Virtual Edition 2020 in HemaSphere: June 2020 - Volume 4; 2020 Jun 11\u201321.","DOI":"10.1097\/HS9.0000000000000404"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.7512"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30909-9"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.76.6840"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00948"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-148666"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-128470"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-10-879429"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14447"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-150914"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.50_2880"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-154195"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.1964020"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00894"},{"key":"e_1_3_5_64_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00807"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-148630"},{"key":"e_1_3_5_66_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-018-0313-8"},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020008164"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30113-9"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(19)30104-8"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2019.223693"},{"key":"e_1_3_5_71_1","doi-asserted-by":"crossref","unstructured":"Davids M Fisher D Tyekucheva S et\u00a0al. A phase Ib\/II study of duvelisib in combination with FCR (DFCR) for frontline therapy of younger CLL patients. Abstract Book for the 23rd Congress of the European Hematology Association Stockholm Sweden June 14-17 2018 in HemaSphere: June 2018 - Volume 2 page 351.","DOI":"10.1097\/HS9.0000000000000060"},{"key":"e_1_3_5_72_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-788133"},{"key":"e_1_3_5_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(20)30433-6"},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.8022"},{"issue":"2","key":"e_1_3_5_75_1","first-page":"29","article-title":"MRD-guided or fixed 12 cycles of venetoclax consolidation after venetoclax plus obinutuzumab treatment in first-line FCR unfit patients with CLL: primary endpoint analysis of the HOVON 139\/GIVE trial","volume":"5","author":"Levin M-D","year":"2021","unstructured":"Levin M-D, Dubois J, Nasserinejad K, et\u00a0al. MRD-guided or fixed 12 cycles of venetoclax consolidation after venetoclax plus obinutuzumab treatment in first-line FCR unfit patients with CLL: primary endpoint analysis of the HOVON 139\/GIVE trial. HemaSphere. 2021;5(S2):29.","journal-title":"HemaSphere"},{"key":"e_1_3_5_76_1","doi-asserted-by":"crossref","unstructured":"Levin MD Kersting S Van Norden Y et\u00a0al. Obinutuzumab pre-induction abrogates high tumor lysis risk of venetoclax in treatment naive FCR-unfit patients with chronic lymphocytic leukemia: a planned interim analysis. Abstract Book for the 23rd Congress of the European Hematology Association Stockholm Sweden June 14-17 2018 in HemaSphere: June 2018 - Volume 2: page 126.","DOI":"10.1097\/HS9.0000000000000060"},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30414-5"},{"key":"e_1_3_5_78_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.69_2629"},{"key":"e_1_3_5_79_1","unstructured":"Kater A Owen C Moreno C et\u00a0al. Fixed-duration ibrutinib and venetoclax (I\u2009+\u2009V) versus chlorambucil plus obinutuzumab (clb\u2009+\u2009O) for first-line (1L) chronic lymphocytic leukemia (CLL): primary analysis of the phase 3 GLOW study. Abstract Book for the 26th Congress of the European Hematology Association Virtual Edition 2021 in HemaSphere: June 2021 - Volume 5 Jun 9\u201317."},{"key":"e_1_3_5_80_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.7501"},{"key":"e_1_3_5_81_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.32_2879"},{"key":"e_1_3_5_82_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2021.1649"},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-139864"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00455-1"},{"key":"e_1_3_5_85_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-09-873083"},{"issue":"2","key":"e_1_3_5_86_1","first-page":"265","article-title":"Impact of unfavorable genetics on minimal residual disease (MRD) response to venetoclax\u2009+\u2009rituximab retreatment in relapsed or refractory chronic lymphocytic leukemia (R\/R CLL): phase 3 MURANO substudy","volume":"5","author":"Wu JQ","year":"2021","unstructured":"Wu JQ, Seymour JF, Eichhorst B, et\u00a0al. Impact of unfavorable genetics on minimal residual disease (MRD) response to venetoclax\u2009+\u2009rituximab retreatment in relapsed or refractory chronic lymphocytic leukemia (R\/R CLL): phase 3 MURANO substudy. HemaSphere. 2021;5(S2):265\u2013266.","journal-title":"HemaSphere"},{"key":"e_1_3_5_87_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.00491"},{"key":"e_1_3_5_88_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-131939"},{"key":"e_1_3_5_89_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01280-8"},{"key":"e_1_3_5_90_1","unstructured":"Rawstron A Webster N Dalal S et\u00a0al. Kinetics of response in the peripheral blood predicts long-term responses to ibrutinib\u2009+\u2009venetoclax treatment for relapsed\/refractory CLL in the Bloodwise TAP Clarity trial. Abstract Book for the 25th Congress of the European Hematology Association Virtual Edition 2020 in HemaSphere: June 2020 - Volume 4; 2020 Jun 11\u201321."},{"key":"e_1_3_5_91_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-146624"},{"key":"e_1_3_5_92_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-146999"},{"issue":"2","key":"e_1_3_5_93_1","first-page":"282","article-title":"Venetoclax-obinutuzumab modulates clonal growth: results of a population-based minimal residual disease model from the randomized CLL14 study","volume":"5","author":"Al-Sawaf O","year":"2021","unstructured":"Al-Sawaf O, Zhang C, Lu T, et\u00a0al. Venetoclax-obinutuzumab modulates clonal growth: results of a population-based minimal residual disease model from the randomized CLL14 study. HemaSphere. 2021;5(S2):282.","journal-title":"HemaSphere"},{"key":"e_1_3_5_94_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-142014"},{"key":"e_1_3_5_95_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2021-149919"},{"key":"e_1_3_5_96_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2019-123404"},{"key":"e_1_3_5_97_1","doi-asserted-by":"crossref","unstructured":"Barr PM Ma S Zent CS et\u00a0al. 1\/2 Study of umbralisib ublituximab and venetoclax (U2-Ven) in patients with relapsed or refractory chronic lymphocytic leukemia (CLL. American Society of Hematology Annual Meeting & Exposition (Virtual)Abstract Book for the 25th Congress of the European Hematology Association Virtual Edition 2020 in HemaSphere: June 2020 - Volume 4; 2020 Dec 7\u201311","DOI":"10.1182\/blood-2020-134818"},{"issue":"2","key":"e_1_3_5_98_1","first-page":"283","article-title":"Minimal residual disease-driven treatment intensification with sequential addition of ibrutinib (IBR) to venetoclax (VEN) in relapsed\/refractory chronic lymphocytic leukemia (CLL): the IMPROVE study","volume":"5","author":"Scarf\u00f2 L","year":"2021","unstructured":"Scarf\u00f2 L, Heltai S, Albi E, et\u00a0al. Minimal residual disease-driven treatment intensification with sequential addition of ibrutinib (IBR) to venetoclax (VEN) in relapsed\/refractory chronic lymphocytic leukemia (CLL): the IMPROVE study. HemaSphere. 2021;5(S2):283\u2013284.","journal-title":"HemaSphere"},{"key":"e_1_3_5_99_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2020-136977"},{"key":"e_1_3_5_100_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-09-806398"},{"key":"e_1_3_5_101_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V124.21.3307.3307"},{"key":"e_1_3_5_102_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2404584"}],"container-title":["Leukemia &amp; Lymphoma"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/10428194.2022.2098291","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,6]],"date-time":"2025-02-06T19:50:35Z","timestamp":1738871435000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/10428194.2022.2098291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,19]]},"references-count":101,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,10,15]]}},"alternative-id":["10.1080\/10428194.2022.2098291"],"URL":"https:\/\/doi.org\/10.1080\/10428194.2022.2098291","relation":{},"ISSN":["1042-8194","1029-2403"],"issn-type":[{"value":"1042-8194","type":"print"},{"value":"1029-2403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,19]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ilal20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2022-05-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}